Sources and Consequences of High Drug Prices in the US: A Health Policy and Bioethics Consortium
High drug costs reduce patient adherence and lead to worse outcomes. The process for translating a drug's price, set by the manufacturer, to cost paid by patients and health care institutions is complex and involves a number of different actors. Can we develop policies that optimize pharmaceutical spending to ensure that patients can access the products they need and to promote cost-effective use of products?
William H. Shrank, Chief Medical Officer, University of Pittsburgh Medical Center Health Plan
Timothy G. Ferris, Senior Vice President, Center for Population Health, and Associate Professor of Medicine, Massachusetts General Hospital and Harvard Medical School
Learn more about the Health Policy and Bioethics Consortia.
The Health Policy and Bioethics Consortia is a monthly series that convenes two international experts from different fields or vantage points to discuss how biomedical innovation and health care delivery are affected by various ethical norms, laws, and regulations. They are organized by the Center for Bioethics at Harvard Medical School and the Program On Regulation, Therapeutics, And Law (PORTAL) at Brigham and Women's Hospital, in collaboration with the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School. Support provided by the Oswald DeN. Cammann Fund at Harvard University